Oramed Reports Fiscal Third Quarter 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 17 2025
0mins
Should l Buy ORMP?
Source: PRnewswire
Strong Financial Performance: Oramed Pharmaceuticals reported a net income of $65 million for the nine months ending September 30, 2025, a significant turnaround from a net loss of $6.1 million in the same period last year.
Asset Growth: The company's total assets increased by 42% year-over-year, rising from $155.3 million to $220.5 million, reflecting robust balance sheet growth.
Investment Returns: The financial improvement was largely driven by cash returns from Scilex Holding Company and unrealized gains from investments in Alpha Tau Medical Ltd. and others.
Management Insights: CEO Nadav Kidron emphasized the effectiveness of their disciplined investment strategy, which has enhanced financial flexibility and supports ongoing development of their oral drug delivery platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORMP
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oramed Pharmaceuticals Reports $10 Million Profit in Q4
- Quarterly Profit Performance: Oramed Pharmaceuticals reported a profit of $10 million in Q4, translating to a net income of $0.24 per share, indicating the company's stability and profitability in the market, although adjusted losses were $0.06 per share due to non-recurring gains.
- Annual Performance Review: For the year, the company achieved a profit of $64.1 million, or $1.50 per share, reflecting sustained growth despite only $2 million in revenue, highlighting a gap between profitability and revenue growth.
- Market Reaction Expectations: Despite low revenue, Oramed's profitability may attract investor interest, especially in the biopharmaceutical sector where improved profitability is often seen as a positive signal for future growth potential.
- Financial Health Status: The company demonstrates strong profitability despite revenue challenges, showcasing potential in cost control and operational efficiency, which may lay the groundwork for future investments and expansion.
See More
LIFEWARD FINALIZES STRATEGIC PARTNERSHIP WITH ORAMED
- Partnership Announcement: LifeWard has successfully closed a strategic partnership with Oramed Pharmaceuticals.
- Focus on Innovation: The collaboration aims to enhance the development of innovative therapies, particularly in the field of diabetes treatment.
See More
LIFEWARD SECURES SHAREHOLDER CONSENT TO FINALIZE STRATEGIC ALLIANCE WITH ORAMED, FORMING A DIVERSIFIED BIOMEDICAL FIRM
Shareholder Approval: LifeWard has received approval from its shareholders to proceed with a strategic partnership.
Partnership with Oramed: The partnership involves collaboration with Oramed, focusing on the development of diversified biomedical solutions.
See More
Analysis of High Dividend Stocks in Healthcare Sector
- High Dividend Stocks: Oramed Pharmaceuticals (ORMP) offers a dividend yield of 7.61%, making it one of the most attractive investment options in the healthcare sector for investors seeking stable income.
- Reliable Income Sources: Embecta (EMBC) and Pfizer (PFE) provide dividend yields of 6.62% and 6.36%, respectively, indicating that the healthcare sector can still deliver reliable cash flow amidst market uncertainties.
- Additional High-Yield Stocks: DENTSPLY SIRONA (XRAY) and National Research (NRC) have dividend yields of 5.02% and 4.39%, respectively, further demonstrating the investment value of the healthcare sector in the current economic climate.
- Market Focus: With oil prices exceeding $100 per barrel and geopolitical tensions, investors are showing strong interest in high-dividend stocks within the healthcare sector, reflecting a demand for stable investment opportunities.
See More
Lifeward Announces 1-for-12 Reverse Stock Split
- Reverse Split Announcement: Lifeward has announced a 1-for-12 reverse stock split effective February 24, 2026, which will reduce outstanding shares from approximately 18.3 million to around 1.5 million, aimed at boosting the share price to comply with Nasdaq's $1.00 minimum bid requirement.
- Authorized Capital Increase: The board also approved increasing the authorized share capital to 100 million shares, providing greater flexibility for future financing and shareholder equity, despite the stock plummeting nearly 20% to an all-time low following the announcement.
- Historical Context: This marks Lifeward's second reverse split since March 2024, when a 1-for-7 split reduced outstanding shares from about 60.1 million to approximately 8.6 million, indicating ongoing adjustments in the company's capital management strategy.
- Partnership with Oramed: Lifeward has partnered with Oramed Pharmaceuticals to integrate its proprietary protein oral delivery technology, which could provide Lifeward with access to up to $47 million in capital, supporting future growth initiatives.
See More
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
- Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
- Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
- Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
See More
Oramed Pharmaceuticals Reports $10 Million Profit in Q4
- Quarterly Profit Performance: Oramed Pharmaceuticals reported a profit of $10 million in Q4, translating to a net income of $0.24 per share, indicating the company's stability and profitability in the market, although adjusted losses were $0.06 per share due to non-recurring gains.
- Annual Performance Review: For the year, the company achieved a profit of $64.1 million, or $1.50 per share, reflecting sustained growth despite only $2 million in revenue, highlighting a gap between profitability and revenue growth.
- Market Reaction Expectations: Despite low revenue, Oramed's profitability may attract investor interest, especially in the biopharmaceutical sector where improved profitability is often seen as a positive signal for future growth potential.
- Financial Health Status: The company demonstrates strong profitability despite revenue challenges, showcasing potential in cost control and operational efficiency, which may lay the groundwork for future investments and expansion.
See More
LIFEWARD FINALIZES STRATEGIC PARTNERSHIP WITH ORAMED
- Partnership Announcement: LifeWard has successfully closed a strategic partnership with Oramed Pharmaceuticals.
- Focus on Innovation: The collaboration aims to enhance the development of innovative therapies, particularly in the field of diabetes treatment.
See More
LIFEWARD SECURES SHAREHOLDER CONSENT TO FINALIZE STRATEGIC ALLIANCE WITH ORAMED, FORMING A DIVERSIFIED BIOMEDICAL FIRM
Shareholder Approval: LifeWard has received approval from its shareholders to proceed with a strategic partnership.
Partnership with Oramed: The partnership involves collaboration with Oramed, focusing on the development of diversified biomedical solutions.
See More
Analysis of High Dividend Stocks in Healthcare Sector
- High Dividend Stocks: Oramed Pharmaceuticals (ORMP) offers a dividend yield of 7.61%, making it one of the most attractive investment options in the healthcare sector for investors seeking stable income.
- Reliable Income Sources: Embecta (EMBC) and Pfizer (PFE) provide dividend yields of 6.62% and 6.36%, respectively, indicating that the healthcare sector can still deliver reliable cash flow amidst market uncertainties.
- Additional High-Yield Stocks: DENTSPLY SIRONA (XRAY) and National Research (NRC) have dividend yields of 5.02% and 4.39%, respectively, further demonstrating the investment value of the healthcare sector in the current economic climate.
- Market Focus: With oil prices exceeding $100 per barrel and geopolitical tensions, investors are showing strong interest in high-dividend stocks within the healthcare sector, reflecting a demand for stable investment opportunities.
See More
Lifeward Announces 1-for-12 Reverse Stock Split
- Reverse Split Announcement: Lifeward has announced a 1-for-12 reverse stock split effective February 24, 2026, which will reduce outstanding shares from approximately 18.3 million to around 1.5 million, aimed at boosting the share price to comply with Nasdaq's $1.00 minimum bid requirement.
- Authorized Capital Increase: The board also approved increasing the authorized share capital to 100 million shares, providing greater flexibility for future financing and shareholder equity, despite the stock plummeting nearly 20% to an all-time low following the announcement.
- Historical Context: This marks Lifeward's second reverse split since March 2024, when a 1-for-7 split reduced outstanding shares from about 60.1 million to approximately 8.6 million, indicating ongoing adjustments in the company's capital management strategy.
- Partnership with Oramed: Lifeward has partnered with Oramed Pharmaceuticals to integrate its proprietary protein oral delivery technology, which could provide Lifeward with access to up to $47 million in capital, supporting future growth initiatives.
See More
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
- Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
- Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
- Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
See More
